Zachary Kockler, BS

Element Iowa City (JMI Laboratories)

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-1203) Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1204) Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in United States Medical Centers (2023)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1213) Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1214) In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1279) Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1287) In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa collected from United States Hospitals during 2020–2024
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1319) Antimicrobial Activity of Aztreonam-Avibactam and Molecular Characterization of Enterobacterales Resistant to Ceftazidime-Avibactam and/or Meropenem-Vaborbactam from United States Medical Centers (2016-2024)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET